Rosetta Genomics Announces OncoGxOne Launch

Israeli devicemaker Rosetta Genomics announced Thursday the launch of OncoGxOne, a next-generation sequencing panel for cancerous genetic alterations detection. This is the company’s fifth new product introduced this year.

The test evaluates all genomic aberrations types in 64 genes, and is meant to be performed in the standard format of formalin fixed paraffin embedded tissue. Rosetta also offers tests for cancer origin, lung cancer and kidney cancer, among others.

The company’s recent purchase of PersonalizeDx broadened its product portfolio to include more bladder, lung, prostate and breast cancer assays.

Rosetta was founded in 2000 to provide microRNA-based molecular diagnostics. — Jason Scott